First successful treatment of pediatric high-risk refractory neuroblastoma with PARP inhibition

Scientists and clinicians at St. Jude Children’s Research Hospital identified the genetic vulnerability BARD1 in a patient with pediatric neuroblastoma, successfully treating the disease with targeted therapy.

Read more: https://www.stjude.org/media-resources/news-releases/2024-medicine-science-news/first-successful-treatment-of-pediatric-high-risk-refractory-neuroblastoma-with-parp-inhibition.html